Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VISX -- Ignore unavailable to you. Want to Upgrade?

To: Bajasurfer who wrote (646)	7/15/1998 5:23:00 PM
From: Jim Mac	Respond to of 1754

Using same tax rate as Q1, Q2 would have been over $0.70. Going forward, Visx will keep all its PRK royalties instead of splitting them with Summit, which should be a net royalty gain for Visx, and a net royalty loss for Summit since Visx systems now doing 70% of all procedures. Add in lower legal and we're talking 1998 fully taxed EPS of $2.33, assuming fully taxed Q EPS of $0.45, 0.58, 0.65, 0.65. That may be low. 1999 might be $3.00 to $4.00 with hyperopia.